CLINICOPATHOLOGIC PECULIARITIES OF NONSPECIFIC ULCERATIVE COLITIS AND CROHN'S DISEASE

 Currently, inflammatory bowel diseases (IBD), in nonspecific ulcerative colitis (NUC) and Crohn's disease (CD), are an extremely urgent problem. The incidence of both ulcerative colitis and Crohn's disease worldwide is increasing every year, and mainly among the working-age population, which makes inflammatory bowel disease (IBD) a socially significant disease. The clinical picture of IBD is diverse, which often makes it difficult to timely diagnose and prescribe adequate therapy and inevitably negatively affects the prognosis of diseases. Here are some of the characteristics of the NUC and CD. The histogram results of numerous studies indicate the following: in Crohn's disease (CD), the thickness of the intestinal wall is often significantly increased. In the mucous membrane, slit-like ulcerative defects are detected, in the bottom of which there are signs of inflammation in the form of infiltration of the bottom of the ulcers by leukocytes, lymphocytes, histiocytes. As for colitis, based on these clinical cases, it can be concluded that children and adolescents are  characterized by a total lesion of the colon and the appearance of segmental forms. In adult patients, distal colitis, the so-called proctosigmoiditis, prevails.  On examination, the mucous membrane was edematous, vividly hyperemic,  edematous, with superficial erosions. 

1. Crohn's disease. Clinical recommendation MH RF. 2020. P. 52

2. Nonspecific ulcerative colitis. Clinical recommendation MH RF. 2020. P. 57

3. Akhrieva Kh. M. Classification and morphological diagnosis of ulcerative colitis and Crohn's disease/ Kh. M. Akhrieva, A. S. Tertychny, I. V. Mayev, O. V. Zairatyants //Clinical and experimental morphology-2017-No. 3 (23) - pp. 4-16

4. Bakulin I. G., Skalinskaya M. I., Skazyvaeva E. V. The place of mesalazine in the treatment of ulcerative colitis//Medical council. - 2017. - N. 15.

5. Belousova E. A., Nikitina N. V., Tsodikova O. M. Treatment of ulcerative colitis of light and moderate severity. Pharmateca. 2013; N 2, p. 42-46.

6. Grigorieva, G. A. Crohn's disease / G. A. Grigorieva, N. Yu. Meshalkina. - M: Medicine, 2007. - 184 p.

7. Livzan, M. A. Inflammatory diseases of the intestine: modern aspects of diagnosis and treatment / M. A. Livzan, M. A. Makeikina / Gastroenterology. – 2012. –№ 2.

8. Sukhina M. A., Obraztsov I. V., Mikhalevskaya V. I., Achkasov S. I., Safin A. L., Shelygin Yu. A. Algorithm for laboratory diagnosis of clostridium difficile-associated diarrhea. Journal of Microbiology, Epidemiology, and Immunobiology (ZHMEI). 2018; (2): 45 - 53.

9. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53: V1 - 16.

10. Parente F, Greco S, Molteni M, et al. Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Alimentary Pharmacology and Therapeutics. 2003; 18: 1009 - 1016.

11. Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 601 - 16.

12. D"Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763 - 86.

13. Chen JH, Andrews JM, Kariyawasam V, Moran N. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul; 44(2): 127 - 44.